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Abstract
This chapter reviews genes and syndromes associated with predisposition to colorectal cancer 
(CRC), with an overview of gene variant classification. We include updates on the application of 
preventive and therapeutic measures, focusing on the use of non-steroidal anti-inflammatory drugs 
(NSAIDs) and immunotherapy. Germline pathogenic variants in genes conferring high or 
moderate risk to cancer are detected in 6–10% of all CRCs and 20% of those diagnosed before age 
50. CRC syndromes can be subdivided into nonpolyposis and polyposis entities, the most common 
of which are Lynch syndrome and familial adenomatous polyposis. In addition to known and novel 
genes associated with highly penetrant CRC risk, identification of pathogenic germline variants in 
genes associated with moderate-penetrance cancer risk and/or hereditary cancer syndromes not 
traditionally linked to CRC may have an impact on genetic testing, counseling and surveillance. 
The use of multigene panels in genetic testing has exposed challenges in the classification of 
variants of uncertain significance. We provide an overview of the main classification systems and 
strategies for improving these. Finally, we highlight approaches for integrating chemoprevention in 
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the care of individuals with genetic predisposition to CRC and use of targeted agents and 
immunotherapy for treatment of mismatch repair deficient and hypermutant tumors.
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Introduction
Colorectal cancer (CRC) is the third most common cancer diagnosed in men and women. 
While there has been an overall decrease in CRC incidence and mortality among individuals 
age 50 and older, recent epidemiological studies demonstrate increasing incidence of CRC 
among young individuals which remains unexplained [1]. Genetic predisposition, due to 
pathogenic germline variants in genes associated with high cancer risk has been implicated 
in 2–8% of all CRCs, 6–10% when considering pathogenic mutations in known high- and 
moderate- penetrance genes [2–4] (1 in 5 of those diagnosed at age<50) [5–7]. For 
individuals with certain hereditary cancer syndromes lifetime risks for CRC may approach 
50–80% in the absence of endoscopic and/or surgical intervention. In addition to family 
history, tumor histology and molecular phenotypes are instrumental not only for identifying 
individuals with genetic predisposition to CRC but also for guiding cancer treatment. The 
following review is an overview of the known CRC predisposing genetic conditions, the 
challenge of variant classification, and chemoprevention and treatment strategies in 
hereditary CRC syndromes.
Genetic Susceptibility to Colorectal Cancer: Polyposis and Non-Polyposis Syndromes
Genetic susceptibility to CRC appears to be more common than previously appreciated. 
Several recent studies have identified pathogenic germline variants in a broad spectrum of 
high and moderate penetrance cancer susceptibility genes in > 10% of individuals with 
advanced cancer diagnoses [8, 9] and the prevalence of 1 in 10 appears to also be true among 
individuals with CRC [2]. In a cohort of unselected CRC patients evaluated at a tertiary care 
cancer center, 105/1058 (9.9%) had pathogenic germline variants identified through next 
generation sequencing with a multigene panel, half of which were in cancer genes not 
previously associated with CRC risk [2]. Genetic susceptibility appears to be even more 
prevalent among young CRC patients, with several studies documenting prevalence of 
germline mutations of 16–33% among those diagnosed age<50 [5–7].
The hereditary CRC syndromes, characterized by dramatic increases in risk for colorectal 
neoplasia, are phenotypically divided into polyposis and nonpolyposis syndromes, based 
largely on the number and histology of colorectal polyps (Figure 1). Tumor molecular 
features characteristic of CRC-predisposing syndromes caused by altered DNA repair are 
shown in Table 1, and current colonoscopy surveillance recommendations for the well-
known high penetrance CRC syndromes, in Table 2.
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Polyposis syndromes—Familial adenomatous polyposis (FAP) is characterized by 
multiple (typically dozens to hundreds) colorectal adenomas, with potential for significant 
variability in clinical phenotype. FAP is associated with pathogenic germline variants in 
APC, a tumor suppressor instrumental in regulation of WNT signaling. While FAP exhibits 
autosomal dominant inheritance, approximately 30% of affected individuals have no family 
history and represent de novo mutations [10]. Phenotypes vary, with some individuals 
exhibiting classic polyposis (100s-1000s polyps) requiring surgical colectomy, while others 
may manifest more subtle presentations (20–100 polyps), often referred to as attenuated 
polyposis (or AFAP). Most individuals with FAP also develop neoplasia in the upper GI 
tract, including gastric fundic gland polyps and duodenal and ampullary 
adenomas..Adenocarcinomas of the duodenum and ampullanowadays represent the second 
leading cause of cancer death after CRC requiring ongoing endoscopic surveillance. 
Although gastric fundic gland polyps rarely exhibit neoplastic transformation, gastric 
adenocarcinomas have been reported. A rare germline point mutations in Exon 1B of APC 
have been identified in individuals with Gastric Adenocarcinoma and Proximal Polyposis 
Syndrome (GAPPS), conferring severe gastric polyposis and high risk for gastric cancer 
without colorectal polyposis [11]. Extraintestinal manifestations in FAP can include 
increased risk for papillary thyroid cancers (particularly the cribiform-morular variant). 
Desmoid tumors develop in some individuals, and mesenteric desmoid disease can be a 
source of significant morbidity and mortality. Although some studies have found 
associations between mutations in codons 543–713 and 1310–2011 and risk for desmoid 
disease [12], factors contributing to desmoid disease remain largely unknown.
MUTYH-associated polyposis (MAP) is an autosomal recessive syndrome associated with 
biallelic germline variants in the base excision repair gene MUTYH. Individuals with MAP 
can exhibit a wide range of phenotypes including classic and attenuated polyposis. Two 
common founder mutations (Y165C and G382D) have a carrier frequency of 1% in 
populations of European ancestry [13]. Monoallelic MUTYH variants have been found to be 
associated with a moderate (1.5–2 fold) increased risk for CRC, particularly among 
individuals with a first degree relative with CRC [14].
Polymerase proofreading-associated Polyposis (PPAP) is associated with germline 
pathogenic variants in the exonuclease (proofreading) domains of polymerases epsilon 
(POLE) and delta (POLD1) [15]. Individuals may present with autosomal dominant classic 
or attenuated polyposis, CRCs and other tumors that exhibit somatic hypermutation, usually 
with DNA mismatch repair proficient phenotypes.
Adenomatous polyposis syndromes have been recently updated with the addition of two rare 
autosomal recessive forms caused by biallelic mutations in NTHL1, a DNA glycosylase 
involved in base excision repair [16], and in MSH3, an MMR gene not associated with 
Lynch syndrome [17].
Hamartomatous polyposis syndromes, characterized by the presence of gastrointestinal 
hamartomatous polyps, are rare, having only one tenth the prevalence of adenomatous 
polyposis syndromes. Hamartomatous polyposis syndromes exhibit autosomal dominant 
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patterns of inheritance, and include Peutz-Jeghers, Juvenile polyposis and PTEN-hamartoma 
tumor syndromes.
Peutz-Jeghers syndrome (PJS) is characterized by multiple hamartomatous polyps 
throughout the GI tract and increased risk for various cancers including gastrointestinal 
(gastric, colorectal, pancreatic), breast, lung, and sex cord tumors. Individuals with PJS may 
have prominent mucocutaneous pigmentation and bowel obstructions due to polyp 
intussusceptions. Germline pathogenic variants in STK11 are identified in 50–70% of 
individuals.
Juvenile polyposis syndrome (JPS) is characterized by multiple gastric and/or colonic 
hamartomas. Germline pathogenic variants in BMPR1A and SMAD4 are identified in 50–
70% of affected individuals. JPS is associated with increased risks for gastric and colorectal 
cancers. Individuals with SMAD4 mutations are at risk for hereditary hemorrhagic 
telangiectasia (HHT).
PTEN-hamartoma tumor syndrome (PHTS) is associated with increased risk for breast, 
thyroid, endometrial, and renal cancers resulting from germline pathogenic variants in 
PTEN. The gastrointestinal phenotype of the PTEN-hamartoma tumor syndrome can include 
gastric and colorectal hamartomas, adenomas, serrated polyps, hyperplastic polyps, lipomas 
and ganglioneuromas. PTEN pathogenic variants confer variable clinical phenotypes, which 
include several conditions such as Cowden, Bannayan-Riley-Ruvalcaba and Proteus-like 
syndromes [18].
Mixed polyposis is characterized by the presence of multiple colorectal polyps of mixed 
histological type, including serrated lesions, conventional adenomas and hamartomas, and is 
associated with increased risk of colorectal carcinoma. While the genetic cause remains 
elusive in most cases, germline variants in and upstream of GREM1 have been identified in 
some affected individuals. A founder mutation consisting of a duplication of 40Kb upstream 
GREM1 has been identified in several kindreds of Ashkenazi Jewish ancestry [19], while a 
duplication of 16kb has been reported in a Swedish family affected with hereditary mixed 
polyposis [20].
Serrated polyposis, previously referred to as hyperplastic polyposis, is defined by the World 
Health Organization on the basis of any of the following criteria 1) ≥5 serrated polyps 
proximal to the sigmoid colon with at least 2 measuring >10 mm; 2) any number of serrated 
polyps in the proximal colon in an individual with a first-degree relative with serrated 
polyposis; or 3) >20 serrated polyps of any size [21]. While germline mutations in the tumor 
suppressor gene RNF43 have been identified in rare cases of serrated polyposis [22, 23], the 
low mutation frequency among affected individuals tempers enthusiasm for including 
RNF43 in multigene panels [24, 25]. Although germline mutations in GREM1 and MUTYH 
have been reported, genetic testing is usually uninformative.
Hereditary nonpolyposis colorectal cancer—Although the CRC syndromes 
associated with polyposis phenotypes are the most easily recognized, the vast majority of 
individuals affected by genetic predisposition to CRC do not exhibit multiple polyps. 
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Syndromic non-polyposis CRC is subdivided on the basis of molecular tumor phenotype as 
DNA mismatch repair deficient (MMR-d) or proficient (MMR-p) (Figure 1).
Lynch syndrome (LS) [previously known as hereditary nonpolyposis colorectal cancer 
(HNPCC)] is the most common of the hereditary CRC syndromes. LS is associated with 
pathogenic germline variants or epimutations in DNA mismatch repair genes (MLH1, 
MSH2, MSH6, PMS2), which predispose to development of neoplasms with distinctive 
molecular phenotypes of MMR-d. MMR-d tumors exhibit high instability at specific DNA 
microsatellites (MSI-H) and loss of expression of the corresponding DNA mismatch repair 
protein by immunohistochemistry. Although CRC and endometrial cancer are the most 
prominent cancers in most affected families, risks for ovarian, gastric, small intestinal, 
urinary tract, brain, pancreatic, prostate and sebaceous neoplasms of the skin are also 
increased among mutation carriers. Lynch-associated colorectal neoplasms tend to develop 
at younger ages and progress more rapidly compared with sporadic CRCs, requiring 
specialized surveillance (Table 2). Although risk prediction models use personal and family 
history to assess an individual’s probability of carrying a germline MMR gene mutation (e.g. 
PREMM1,2,6 [26], MMRpro [27]), universal screening of CRC tumors for MMR-d remains 
the most effective strategy for identifying individuals affected with LS (Figure 2) [28, 29].
MMR-proficient hereditary nonpolyposis colorectal cancer.: Half of CRC families 
meeting Amsterdam criteria (3 individuals with CRC over 2 generations, ≥1 diagnosed 
age<50) have MMR-p tumors, without identifiable germline mutations in the MMR genes. 
These families can be distinguished from LS in that the lifetime risk for CRC is lower (only 
2-fold increased) and there is no increase in risks for extracolonic tumors [30]. Despite 
enormous efforts to identify new genes that could explain the apparently dominantly 
inherited forms of MMR-p nonpolyposis CRC, the only candidate gene that has shown 
consistent association with hereditary nonpolyposis CRC is RPS20 (ribosomal protein S20) 
[31, 32]. Although the scarce available data suggest high penetrance for RSP20 mutations 
and absence of extracolonic manifestations, data from additional mutation carriers are 
required to estimate risks and recommend surveillance measures. Many other putative 
familial CRC genes have been proposed, but most are extremely uncommon, and others may 
only moderately increase the risk to CRC, complicating the assessment of their contribution 
to predisposition to CRC [33–36].
Prevalence and penetrance
The prevalence of mutations in CRC-predisposing genes has traditionally been estimated 
from patients diagnosed with CRC (or endometrial cancer for LS). This approach reveals 
that LS accounts for about 3% of CRC [2, 37–40] and 2% of endometrial cancer cases [41–
43]; additionally, FAP accounts for 0.3–0.5% of diagnosed colorectal tumors [2, 3]. When 
LS is ascertained from individuals with a personal/familial history of cancer, germline 
mutations in MSH2 and MLH1 consistently account for the majority of LS cases (60–
87.5%), with a minority of cases carrying mutations in MSH6 and PMS2 [2, 5, 6, 37, 39, 
44].
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Recent epidemiologic data have shed more light on the true prevalence of LS in the general 
population, finding that LS is more common and less penetrant than traditionally estimated. 
Recently, Win et al. studied 5,744 CRC patients and 37,634 first-degree relatives, 2% of 
whom had been diagnosed with CRC, recruited through the Colon Cancer Family Registry 
[45] (http://coloncrf.org) and for whom germline genetic testing results were available [46]. 
They estimated that 0.36% (1 in 279) of the population carry pathogenic mutations in the 
MMR genes: 0.140% (1 in 714) in PMS2, 0.132% (1 in 758) in MSH6, 0.051% (1 in 1,946) 
in MLH1and 0.035% (1 in 2,841) in MSH2. Regarding MUTYH, 2.2% (1 in 45) would be 
monoallelic and 0.012% (1 in 8,073), biallelic carriers. Interestingly, pathogenic variants in 
PMS2 and MSH6 are the most prevalent in the general population, but least prevalent among 
LS cases ascertained based on their personal history of cancer, suggesting that the PMS2 and 
MSH6 mutations confer more modest risk of cancer when compared with MLH1 and MSH2 
mutations [47–53]. Of note, the presence of founder mutations in specific populations may 
increase the prevalence of the syndrome and influence the relative proportion of mutations in 
each gene in those populations [54–58].
For other less common CRC syndromes, the estimated prevalence is very low, ranging from 
1 in 10,000–31,250 for APC-associated adenomatous polyposis [59, 60], to 1 in 100,000–
250,000 for hamartomatous polyposis syndromes [61–63]. The prevalences of more recently 
described syndromes, such as those caused by mutations in POLE and POLD1, NTHL1, 
RNF43 or MSH3, remain unknown.
Significant interpatient heterogeneity exists among patients with a priori the same CRC 
predisposing syndrome, posing challenges for diagnosis and clinical management. For years, 
lack of prospectively-obtained information has led current clinical guidelines to rely upon 
retrospective data from patient cohorts whose selection for molecular testing was biased 
(CRC risk estimates from retrospectively collected cohorts were reviewed by Lorans et al. 
[64]). The Prospective LS Database (PLSD) provides estimates of cancer risks in LS, both in 
individuals who have yet to develop a cancer and those who have survived a cancer (http://
lscarisk.org/). According to these data, the relative cumulative incidence (relative risk) of 
cancer at age 75 is: 10–12% for CRC and 25–35% for endometrial cancer in MLH1 and 
MSH2 mutation carriers; 30% for endometrial cancer in MSH6 mutation carriers, and for 
PMS2, the increased cancer risks did not reach statistical significance when compared to 
population incidence [65]. More recently, the analysis of 284 families, including 4,878 first- 
and second-degree family members, 513 of whom were PMS2 mutation carriers, concluded 
that PMS2 mutation carriers are at small increased risk of CRC (cumulative risk at age 80: 
12–13%) and endometrial cancer (cumulative risk at age 80 for female carriers: 13%) [66].
In addition to the gene-specific risks, cancer risks in hereditary CRC syndromes may also 
vary by the type of mutation, ethnicity or geographic location. There is heterogeneity even 
among family members sharing the same mutation, suggesting that other factors, such as 
environmental and polygenic factors may influence phenotypic expression [67].
Moderate-penetrance colorectal cancer gene mutations
The inclusion of moderate-penetrance cancer susceptibility genes in multigene panel testing 
poses challenges regarding the optimal management of carriers of pathogenic mutations in 
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these genes. In fact, the associated clinical significance of these mutations remains unclear. 
In the case of CRC, the most prevalent mutations are APC p.I1307K, CHEK2 c.1100delC, 
CHEK2 p.I157T, and monoallelic MUTYH mutations [2] (Figure 1). Recently, Katona et al. 
[68] defined a counseling framework for these moderate-penetrance mutations based on the 
estimated CRC risk associated with each variant [69] and the estimated CRC risk for 
average-risk individuals [70 April 2017. #171]. Based on this analysis, colonoscopy 
screening initiation is recommended at age 45 (at age 50 for average-risk individuals [71]) 
for APC p.I1307K and CHEK2 mutation carriers, however, no earlier initiation of 
colonoscopy screening is recommended for monoallelic MUTYH mutation carriers, in line 
with current National Comprehensive Cancer Network recommendations [71]. Such 
recommendations apply to patients without family history of CRC; importantly, however, 
earlier and more frequent colonoscopy screening is recommended for individuals with a 
family history of CRC, even in the absence of gene-based findings [72].
Mutations in genes associated with hereditary cancer syndromes not traditionally linked to 
CRC
Both classical testing strategies and multigene panel tests in CRC cases have uncovered 
germline pathogenic variants in cancer susceptibility genes associated with syndromes that 
do not classically include CRC, such as hereditary breast and ovarian cancer syndrome. 
Studies with several hundred up to roughly 2,000 CRC cases and controls have yielded 
evidence for ATM, BRCA1, BRCA2, CDKN2A, PALB2, and TP53 as moderate-risk CRC 
susceptibility genes (Table 3). The most frequently mutated non-CRC hereditary genes 
identified in CRC patients are BRCA1 and BRCA2 (0.7–1.3% of CRC patients, regardless 
of selection criteria), followed by the moderate-penetrance gene ATM (0.7–0.9% of CRC 
patients, regardless of selection criteria). The debate whether pathogenic BRCA mutations, 
or mutations in any of the above mentioned genes, increase the risk of CRC is still ongoing. 
A recent meta-analysis based on 14 studies [73] estimated a 1.22-fold increased risk of CRC 
in BRCA mutation carriers, and this was attributable largely to a 1.48-fold greater risk in 
BRCA1 mutation but not in BRCA2 mutation carriers, regardless of age.
Whether these findings are the result of detecting the background population prevalence of 
such mutations or the result of pleiotropism, i.e., a germline variant manifests itself in a 
variety of clinical phenotypes, which would suggest that, for example, BRCA1/BRCA2 
mutations increase the risk to CRC, is still a matter of debate. In order to clarify the 
contribution of non-CRC susceptibility genes to CRC predisposition, Dobbins et al. 
analyzed 114 hereditary cancer genes in approximately 850 unexplained early-onset/familial 
CRC and 1,609 controls. Globally, no statistically significant enrichment of pathogenic and 
likely pathogenic variants was detected between cases and controls (6.7% vs. 5.3%), not 
even for BRCA or TP53 mutations, thus arguing against the hypothesis supporting 
pleiotropism [74]. Recently, AlDubayan et al. evaluated the presence of germline mutations 
in 40 DNA repair genes linked to (non-CRC) inherited cancer predisposition in 591 
unselected CRC patients from two prospective population-based studies and 89 clinic-based 
unselected CRC patients (total n=680) and compared the mutation frequency with that 
observed in 27,728 ancestry-matched cancer-free adults from the Exome Aggregation 
Consortium (ExAC). This study revealed significantly higher rates of ATM and PALB2 
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mutations in CRC patients than in cancer-free controls, results that were independently 
validated in 1,661 unselected CRC patients for both genes and in 1,459 early-onset (age<56) 
CRC patients only for ATM [3]. On the other hand, no differences were observed for 
BRCA1 and BRCA2 or other non-CRC DNA repair genes. The consequences of one or the 
other situation (background population mutation prevalence vs. pleiotropism) are different 
and highly relevant for the management of the families, therefore, requiring further research 
to provide definitive evidence.
Genetic testing for predisposition to CRC
The well-established, clinically-actionable susceptibility genes with quantified magnitude of 
risk form the core of current familial CRC and polyposis genetic testing (Table 3). In recent 
years, clinical genetic testing has transitioned from phenotype-driven single gene sequencing 
to multigene panel testing using targeted massively parallel sequencing. The criteria for 
identifying individuals most likely to benefit from genetic testing continue to evolve along 
with our understanding of the variability in disease penetrance and expressivity associated 
with germline alterations in cancer predisposition genes [71].
Overview on variants of uncertain significance
When patients are tested for germline susceptibility gene mutations, most outcomes fall into 
one of three categories: a pathogenic variant is found, a variant of uncertain significance 
(VUS) is found, or no reportable variant is found. When a pathogenic variant is found, 
patients can be counseled and managed on the basis of their personal and family cancer 
history plus gene-specific guidelines. “Cascade testing” of at-risk relatives can identify 
additional carriers. These newly identified carriers benefit because they can be offered 
earlier and intensified screening; this is particularly valuable for CRC syndromes because 
there is credible evidence that exposure to colonoscopy reduces incidence and mortality 
from CRC [75, 76]; put simply, cascade testing followed by intensified screening of carriers 
can add years to these individuals’ lives. Non-carriers benefit from knowing that their CRC 
risk is lower than that of carriers in their family, and may be spared intensified family 
history-based screening [77, 78].
Observation of a VUS presents a quandary, since it is not known where on a spectrum from 
pathogenic to benign any given VUS falls, carrier status does not stratify members of a 
family into those with higher or lower risk. Thus, detection and reporting of the VUS 
provides no medical management benefit to sentinel carriers or their relatives. Unfortunately 
physicians may misinterpret or miscommunicate a VUS test result, resulting in management 
of a patient with a VUS as if they carried a pathogenic variant, which is clearly incorrect 
[79, 80]. Moreover, there is a lack of tools for updating clinical oncologists and genetic 
counselors after a VUS has been reclassified [81].
Main categories of variants of uncertain significance
Most VUS fall into one of three categories: missense substitutions, splice junction variants, 
and in-frame insertion or deletions variants (in-frame indels), with missense substitutions 
being the most numerous. Because of the patterns biophysical similarity and dissimilarity 
between the 20 naturally occurring amino acids, a missense substitution can fall anywhere in 
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a spectrum from innocuous to ablating protein function to creating new protein functions. 
Similarly, because splicing machinery has varying dependencies on the individual nucleotide 
positions within splice donor and splice acceptor consensus sequences, sequence variants 
within these regions may ablate, reduce, or even increase the efficiency of splicing at the 
affected intron-exon junction.. Thus, the key analytic problem is that the effects of VUS 
need not to be all-or-none. Whether variants are assayed one-by-one or en masse using high-
throughput gene editing techniques, it is difficult to determine what proportion reduction of 
normal function from a damaged protein, or of productive transcript from a damaged allele, 
is required to confer clinically relevant increased risk of cancer [82–88].
A second problem is that VUS are individually very rare, but summed across the population, 
numerous. Indeed, in a study of the ExAC data, Kobayashi et al. found that most pathogenic 
variants with continental population allele frequencies above 0.01% are already well 
characterized [89]; this means that most VUS (at least for dominant CRC susceptibility 
genes) with allele frequencies of above 0.01% are actually neutral. Yet on reviewing the lists 
of MLH1 and MSH2 sequence variants recorded in the InSiGHT and gnomAD databases, 
we found 1,299 distinct VUS missense substitutions (Table 4). This is just the tip of the 
iceberg, as, based on the estimated per generation germline de novo mutation rate and the 
size of the human population [90, 91], the human gene pool actually includes multiple 
missense substitutions at most protein coding codons, and most of these are pedigree-
specific.
Variant classification frameworks
In 2008, an International Agency for Research on Cancer (IARC) Working Group on VUS 
in cancer susceptibility genes created the five-tiered variant classification scheme shown in 
Table 5 [92]. This scheme was adopted by the International Society for Gastrointestinal 
Hereditary Tumors (InSiGHT), and with minor modification for general use, by the 
American College of Medical Genetics and Genomics and the Association for Molecular 
Pathology (ACMG/AMP) [86, 93].
There are two basic frameworks for variant classification: qualitative rules-based and 
quantitative Bayesian classifications. Since methods for evaluation of VUS in LS genes are 
better developed than for most other CRC susceptibility genes, this discussion will focus on 
evaluation of MMR gene VUS. The essence of rules-based classification is to set up a series 
of points of evidence, and then to define rules governing which combinations of evidence 
result in a specific categorical classification. Data used in the qualitative InSiGHT MMR 
gene variant classifier [86, 87] fall into two broad categories: i) patient observational data, 
such as details of the patient’s personal and cancer family history, segregation (or not) in 
pedigrees, or presence (or not) of MSI in tumors with the VUS; and ii) variant specific data 
such as sequence analysis evidence, functional assay results including mismatch repair 
proficiency and protein stability assays, mRNA splicing assays, and allele frequency in 
control populations. Rules that result in classification as Pathogenic can use stand-alone data 
such as the variant is a protein truncating variant in a coding exon other than the final exon, 
or combine several pieces of individually weaker data such as reduced activity in a 
functional assay plus co-segregation with CRC plus multiple tumors with MSI plus very low 
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allele frequency in continental level populations. There are also corresponding rules for 
classification as Not Pathogenic. For a succinct summary, see Figure 1a of Thompson et al., 
2014 [86]. Critically, if a variant is not associated with enough data to meet either of the 
Pathogenic or Not Pathogenic rules, then it will be classified as VUS.
Bayesian classification views the points of evidence as data. Each data type is calibrated so 
that it can be re-expressed as a prior probability of pathogenicity (Prior_P), odds in favor of 
pathogenicity (Odds_Path), or a likelihood ratio (LR) in favor of pathogenicity. The data 
from each individual sequence variant are then combined using Bayes’ rule to obtain a 
posterior probability of pathogenicity (Post_P). The Post_P is then interpreted through a 
quantitative classifier [92] to obtain the categorical classifications (Table 5).
The challenge with quantitative classification is to calibrate the data types – i.e., to convert 
from the units in which each type of data is naturally expressed to Odds_Path, LR, or 
Prior_P. For classification of MMR gene variants, data that have been calibrated include: a 
sequence analysis-based Prior; segregation in pedigrees; and degree of MSI in CRC tumors 
combined with somatic BRAF mutation status [86, 94, 95].. Because MSI plus BRAF status 
can be detected by somatic tumor mutation screening, this datum will become more widely 
available as tumor screening takes off [96].
Functional assays could make and important contribution to VUS classification [93, 97, 98]. 
Noting that failure of mismatch repair is thought to be the key molecular defect underlying 
LS, de Wind and colleagues developed an in vitro MMR Activity (CIMRA) assay [99–101], 
which has now been calibrated to convert % wild-type activity into CIMRA Odds_Path 
[102]. When the sequence analysis Prior_P and CIMRA assay provided concordant evidence 
in favor of pathogenicity, results met the IARC Likely Pathogenic criterion that >95% of 
variants should actually be pathogenic. On the other hand, when the sequence analysis 
Prior_P and CIMRA assay provided concordant evidence against pathogenicity, results fell 
short of the IARC Likely Not Pathogenic criterion that <5% of variants should be 
pathogenic [86, 87, 102]. In fact, this asymmetry is somewhat expected because a purely in 
vitro assay is intrinsically not able to detect functional defects such as loss of subcellular 
localization or reduced protein half-life.
In their 2017 update to the MMR gene variant classification system, Tricarico and 
colleagues argued that “variants attaining thresholds for assignment to clinically actionable 
classes … with limited contribution from clinical or laboratory evidence be considered of 
uncertain significance until further evidence is accrued” [87]. Whether integrated into LS 
variant classification through the rules-based or quantitative Bayesian approach, the 
systematic application of the computational Prior_P and CIMRA assay is likely to 
dramatically accelerate classification to Likely Pathogenic of missense substitutions 
observed in patients with CRC or other LS spectrum tumor. Further acceleration may be 
possible if the high-throughput gene editing techniques that Findlay et al. recently applied to 
BRCA1 sequence variants can be applied to MMR VUS [85].
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Precision medicine in hereditary colorectal cancer syndromes
Precision Prevention—Among patients with FAP and other polyposis syndromes, 
prophylactic surgery continues to be the current gold standard for prevention of CRC. 
However, those patients that elect rectal-sparing surgeries continue to develop adenomas, 
thus retaining an excessive risk for rectal cancer. Also, duodenal cancer has become a major 
cause of mortality among the FAP population. Therefore, the development of 
chemopreventive agents is still an unmet need in the care of patients with polyposis 
syndromes. Initial studies focused in the efficacy of non-steroidal anti-inflammatory drugs 
(NSAIDs) and more specifically Sulindac, Aspirin and COX-2 inhibitors. Sulindac was the 
first NSAID to show an effect decreasing the number and size of polyps in a cohort of 22 
patients compared with placebo (44%, P=0.014; and 35%, P<0.001, respectively) [103]. 
Subsequently, a follow-up randomized double-blind placebo-controlled study was launched 
for primary prevention. Unfortunately, this study was only able to accrue 41 FAP patients 
and therefore was underpowered, which led to no significant differences in the number of 
polyps between the two arms [104]. The field moved next to explore agents with specificity 
for inhibition of COX-2. Celecoxib demonstrated that treatment of pre-surgical patients with 
2 different doses (100 and 400 mg daily) reduced the number and burden of polyps with 
excellent tolerance from the safety standpoint in this young population.[105, 106]. However, 
the translation of Celecoxib into the general population rendered an unacceptable 
cardiovascular toxicity profile (2.5% of subjects in the Celecoxib group and 1.9% in the 
placebo group) and the drug development was halted despite of a reduction on the 
occurrence of adenomas (RR 0.64; 95% CI, 0.56 to 0.75) [107, 108]. Based on the safety 
data developed in sporadic populations, the benefit of regular use of coxibs in terms of 
delaying the growth of polyps and delaying prophylactic surgery in patients with FAP needs 
to be weighed against the risk of toxic cardiovascular effects. Since the onset of polyps in 
patients with FAP begins occurring during the teenage years, the toxicity profile of coxibs in 
these patients with FAP may be essentially different from that in the general population. In 
fact, Lynch et al. demonstrated that Celecoxib at a dose of 16 mg/kg/day in children (10–14 
years) with FAP is safe, and generated a significant reduction of the number of colorectal 
polyps [109]. Given the cardiovascular toxicity of coxibs, the focus of chemopreventive 
efforts in FAP turned to Aspirin and combinations of Sulindac with other agents. The 
Concerted Action Polyp Prevention (CAPP) group completed an international, multicenter, 
randomized, placebo-controlled trial (CAPP1 protocol) of Aspirin (600 mg daily) and/or 
resistant starch (30 mg daily) in young FAP patients [110]. After 17 months of treatment, the 
primary endpoint to observe a decrease in the polyp number in the rectum and sigmoid colon 
failed. Noteworthy, the diameter of the largest polyp detected by endoscopy at the end of 
intervention tended to be smaller in the Aspirin group (P=0.05). On the combination side, 
DMFO plus Sulindac is being explored as chemoprevention in FAP (NCT01483144) after 
the remarkable activity demonstrated in a phase III with 375 patients with history of resected 
adenomas for prevention of polyp recurrence [111]. Finally, chemoprevention of duodenal 
adenomas in FAP has made significant advances recently with the publications of the results 
of a clinical trial combining Sulindac and Erlotinib on preventing duodenal neoplasia [112]. 
This was a double-blind randomized placebo-controlled study including 92 FAP participants 
that were given 150 mg of Sulindac twice daily combined with 75 mg of Erlotinib once 
daily. The end point of the trial was met and a 71% reduction in duodenal polyp burden was 
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observed between the treatment and placebo groups. This combination also rendered 
substantial modulation of the colorectal adenoma burden [113].
Aspirin has been the primary NSAID explored for chemoprevention in LS. In the CAPP2 
study, a total of 861 LS patients were given 600 mg of Aspirin or placebo for up to 4 years 
[114–116]. Overall, 600 mg of Aspirin given over an average of 25 months was found to be 
effective in reducing CRC occurrence in LS patients. As a follow-up CAPP-3, which is a 
non-inferiority clinical trial, is now being conducted to study the long-term effect of Aspirin 
in 3000 LS patients at three different doses: 100, 300, or 600 mg per day [114]. We have 
recently completed a multi-center Phase Ib biomarker, placebo-controlled, trial of Naproxen, 
an NSAID with improved safety profile [117], in a total of 80 LS patients (NCT02052908). 
All participants underwent colonoscopy before and after the intervention as well as 
collection of blood, plasma, tissue, and urine for subsequent biomarker studies with mRNA-
seq, miRNA-seq and determination of levels PGE2 in tissue, Naproxen in blood and plasma, 
and PGM in urine. The primary endpoint of this trial was safety and modulation of PGE2 
levels in tissue. This study has completed accrual and the data is currently being analyzed 
[118].
Precision treatment: The role of immuno-oncology (IO) in hereditary CRC 
syndromes—IO has become a reality in the treatment of patients with hypermutant 
cancers in general and also in CRC displaying MSI. The activation of the immune system 
developed inn this type of tumors was noted several decades ago by pathologists that 
observed extensive involvement by tumor-infiltrating lymphocytes (TILs) located mainly at 
the invasive front [119]. In fact, the presence of TILs became a standard pathology criterion 
for the diagnosis of sporadic and hereditary MSI tumors [120].
Tumors with a germline MMR mutation must acquire a second somatic hit in the alternate 
allele of the same gene in order to become hypermutant. The inactivity of one of the 
heterodimers of the MMR complex (either the MutL or MutS complexes) leads to the 
accumulation of frameshift mutations that generate neoantigens [121–123]. Some of these 
neoantigens will be processed, presented by the HLA system (HLA-I and II), and recognized 
as foreign by T-cells. In fact, high levels of infiltration by activated CD8-positive cytotoxic T 
lymphocytes and activated Th1 cells with associated IFNγ production has been confirmed in 
detailed immune-pathologic studies. In order to counterbalance this active immune 
environment, multiple immune checkpoints such as PD-1, PD-L1, CTLA-4 and others are 
then activated by tumor cells, thus making them particularly susceptible to immune check-
point blockade [124].
All of these data provided the biologic rationale for two phase II clinical trials assessing the 
activity of checkpoint inhibitors in MSI/Hypermutant tumors. The first trial demonstrated 
that Pembrolizumab, a humanized monoclonal anti-PD-1 antibody, given as single agent 
induced an immune-related objective response rate of 40% and an immune-related 
progression-free survival rate at 20 weeks of 78% in patients with metastatic MSI CRC 
[125]. This exceptional activity contrasted with almost negligible response observed among 
microsatellite stable (MSS)/non-hypermutant tumors. Of note, there were also no significant 
differences in the objective response rate between LS- and non-LS-associated tumors (46% 
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versus 59%, respectively) [126]. The second trial tested Nivolumab, which is another IgG4 
PD-1 blocking antibody, and also demonstrated activity as a single agent and in combination 
with Ipilimumab, a fully human immunoglobulin monoclonal anti-CTLA4 antibody, thus 
providing double checkpoint blockade. 31.1% of patients treated with single agent 
Nivolumab achieved an objective response rate with disease control for 12 weeks or longer 
in 51% [127]. The combination of both checkpoint inhibitors expanded further these results 
and 55% of treated patients achieved an objective response rate, and disease control rate for 
more than 12 weeks was present in 80% of the patients [128]. This remarkable antitumoral 
activity showed by checkpoint inhibitors led the FDA to approve the use of Pembrolizumab 
in May of 2017, then Nivolumab in July of 2017, and later the combination of Ipilimumab 
with Nivolumab in July 2018 for the treatment of stage IV hypermutant/MSI tumors after 
progression to standard chemotherapy. Therefore, these advances have placed hereditary 
CRC syndromes at the epicenter of precision medicine and immune-oncology in the last 2 
years.
Summary
CRC remains one of the most prevalent cancers, but it is also preventable. Making the 
diagnosis of genetic predisposition to CRC provides opportunities for precision cancer 
treatment, early detection, as well as prevention of subsequent cancers in patients and their 
at-risk relatives. Implementation of routine screening of CRC tumors for DNA MMR 
deficiency has been shown to improve detection of Lynch Syndrome beyond family history 
criteria alone. As new strategies for surveillance and chemoprevention provide opportunities 
to reduce morbidity and mortality for individuals with Lynch Syndrome, FAP and other 
genetic diagnoses, it is increasingly important to implement effective strategies to improve 
identification and management of presymptomatic individuals at high risk for CRC.
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Phenotypic classification of nonpolyposis and polyposis CRC syndromes, mode of 
inheritance, causal genes and affected molecular pathways.
Note: Germline AXIN2 autosomal dominant mutations (Wnt pathway) may cause 
oligodontia-colorectal cancer syndrome characterized by severe permanent tooth agenesis 
and the presence CRC or precancerous colonic or gastric lesions of variable types 
(adenomas, hyperplastic polyps) [132–134]. Due to the still undefined CRC and polyposis 
phenotype, it has not been included in the figure.
Abbreviations: BER, base excision repair; CMMRD, constitutional mismatch repair 
deficiency; HMPS, hereditary mixed polyposis syndrome; MAP, MUTYH-associated 
polyposis; MMR, DNA mismatch repair; PPAP, polymerase proofreading-associated 
polyposis; SPS, serrated polyposis syndrome.
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Strategy for universal tumor screening for Lynch syndrome in CRC patients (Adapted from 
Hampel et al. 2018 [29]). The different etiologies of MMR-d CRCs are: i) germline MMR 
gene mutation; ii) serrated pathway lesions (somatic BRAF mutation and/or MLH1 
promoter hypermethylation); iii) double somatic MMR gene mutations; iv) somatic MMR 
gene mutation secondary to a POLE or POLD1 exonuclease mutation or to biallelic 
MUTYH mutations.
Abbreviations: CRC, colorectal cancer; IHC, immunohistochemistry; MMR, DNA mismatch 
repair; MMR-d, mismatch repair deficient; MSI, microsatellite instability; MSI-H, high level 
of microsatellite instability (microsatellite unstable); NGS, next generation sequencing.
Valle et al. Page 22

























Valle et al. Page 23
Table 1.
Molecular alterations detected in the tumors developed by carriers of germline mutations in DNA repair genes.
Syndrome Causal gene Tumor molecular
features COSMIC mutational signatures
b
Lynch syndrome MSH2 MSI Single base substitution: SBS6, SBS15, SBS21, SBS26, SBS44
MLH1 IHC: loss of MMR protein Doublet base substitution: DBS7, DBS10
MSH6 hypermutated Insertion and deletion: ID7, (ID1), (ID2)
PMS2
PPAP POLEa Ultramutated Single base substitution: SBS10a, SBS10b, SBS14 (concurrent POLE mutation and MMR deficiency), SBS20 (concurrent 
POLD1 mutation and MMR deficiency) Doublet base 
substitution: DBS3POLD1
a ↑C:G>A:T (context TCT)
↑C:G>T:A (context TCG)









Biallelic MSH3 MSI of di- and tetranucleotides 
(EMAST)
-
CMMRD Bilalellic MSH2, MSI See Lynch syndrome
MLH1, MSH6, IHC: loss of MMR protein
PMS2 (tumor and normal tissues)
a.
Mutations affecting the proofreading (exonuclease) activity of the polymerases.
b.
Alexandrov et al. 2018 [129].
Abbreviations: CMMRD, constitutional mismatch repair deficiency; EMAST, elevated microsatellite alterations at selected tetranucleotide repeats; 
IHC, immunohistochemistry; MAP, MUTYH-associated polyposis; MMR, DNA mismatch repair; MSI, microsatellite instability; PPAP, 
polymerase proofreading-associated polyposis.
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Table 2.
Colonoscopy surveillance recommendations for individuals with germline pathogenic variants (high 
penetrance syndromes) [130].
Syndrome (Gene) Family history of CRC Age at CRC screening initiation Screening interval if no adenomas
No mutation




FAP (APC) N/A 10–15 1 year, colectomy if polyps too numerous
Lynch syndrome (MLH1, MSH2, 
MSH6, PMS2)
N/A 20–25 1–2 years until age 40, then every 1 year
MAP (MUTYH Biallelic) N/A 25–30 1–3 years depending on polyp burden
Juvenile polyposis (SMAD4, 
BMPR1A)
N/A 15 1–3 years depending on polyp burden
Peutz-Jeghers (STK11) N/A 15 2–3 years depending on polyp burden
Li Fraumeni (TP53) N/A 20–25 3 years
Hereditary Breast No 50 10 years
Ovarian Cancer Yes 50 or per family history 5 years
(BRCA1/BRCA2)
a.
Recommendations based in the guidelines from the National Comprehensive Cancer Network [71].
b.
40 years old or 10 years earlier than the youngest-onset CRC in the family.
Abbreviations: CRC, colorectal cancer; FDR, first-degree relative; SDR, second-degree relative.
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Table 3.
Characteristics and results of key published studies on multigene germline testing for CRC predisposition.
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age <50 evaluated by 
USA Germline DNA 
sequencing (n=293)
High penetrance
13.0% MMR gene (Lynch sd.)
High penetrance
0.5% TP53
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Study Tested patients Country Multigene panel Hereditary CRC genes Other cancer
genes
a


















274 patients (263 
families) fulfilling 
the Amsterdam 
(n=262) or revised 
Bethesda (n=12) 


























The causal role of these genes in CRC predisposition has not been unequivocally proven.
b.
NTHL1, MSH3, POLE and POLD1 and RPS20 are not included in the panel.
c.
NTHL1, POLE and POLD1 and RPS20 are not included in the panel.
d.
NTHL1 and RPS20 are not included in the panel.
e.
Previously identified MMR mutation carriers had been excluded from the analysis.
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Table 4.
MLH1 and MSH2 missense substitutions in the InSiGHT and gnomAD databases.
Variant class and source Missense substitution count Average sequence analysis-based
probability of pathogenicity
Class 4, 5 144 0.784
InSiGHTonly 135 0.790
InSiGHT and gnomAD 9 0.690
Class 3 1,299 0.391
InSiGHTonly 408 0.579
InSiGHT and gnomAD 176 0.388
gnomAD 891 0.306
Class 1, 2 45 0.260
InSiGHTonly 5 0.374
InSiGHT and gnomAD 40 0.246
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Table 5.
The IARC variant classification scheme (Modified from Plon et al. 2008 [92]).
Category Synonym Definition
Pathogenic Post_P> 0.99
Likely Pathogenic 0.99 ≥ Post_P> 0.95
VUS Unclassified variant (UV) 0.95 ≥ Post_P ≥ 0.05
Likely Not Pathogenic Likely Benign 0.05 >Post_P ≥0.001
Not Pathogenic Benign Post_P< 0.001
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